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he SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V
verolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects
ith De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of
he XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of
ubjects With De Novo Native Coronary Artery Lesions) Randomized Trials
ean J. Kereiakes, MD,* Krishnankutty Sudhir, MD, PHD,‡ James B. Hermiller, MD,§
aul C. Gordon, MD, Joanne Ferguson, RN,‡ Manejeh Yaqub, MD,‡
oornima Sood, MD, MBA,‡ Xiaolu Su, MS,‡ Steven Yakubov, MD,†
lexandra J. Lansky, MD,¶ Gregg W. Stone, MD¶
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bjectives We evaluated outcomes following XIENCE V everolimus-eluting stent (EES) compared
ith the Taxus Express2 paclitaxel-eluting stent (PES) in patients undergoing multilesion and mul-
ivessel intervention.
ackground The optimal revascularization strategy for patients with multivessel disease is unknown.
ethods The SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting
oronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions)
n  1,002) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the
reatment of Subjects With De Novo Native Coronary Artery Lesions) (n  3,690) trials enrolled patients with
e novo lesions 28 mm in length and reference vessel diameter of 2.5 to 3.75 mm. The SPIRIT III trial en-
olled patients with a single lesion in 1 or 2 coronary arteries, and the SPIRIT IV trial enrolled patients with up
o 2 lesions in 3 different vessels (maximum 2 lesions per vessel). In both trials, patients were randomized 2:1
o EES vs. PES. Clinical outcomes to 1 year were analyzed in patients with single (n  3,823) versus multiple
n  765) treated vessels, and in those with single (n  3,536) versus multiple (n  1,052) treated lesions.
esults Among patients with multivessel disease, EES compared with PES resulted in reduced rates
f target vessel myocardial infarction (2.2% vs. 6.1%, p  0.007) and ischemia-driven target lesion
evascularization (4.2% vs. 8.0%, p  0.04). Among patients undergoing multilesion stenting, EES
ompared with PES resulted in reduced rates of target vessel myocardial infarction (2.1% vs. 5.4%,
 0.008) and ischemia-driven target lesion revascularization (3.7% vs. 7.4%, p  0.01). The abso-
ute beneﬁts of EES versus PES in patients undergoing multivessel or multilesion intervention were
reater than in those undergoing single-lesion, single-vessel intervention.
onclusions The EES compared with PES provided signiﬁcant improvements in clinical safety and efﬁ-
acy outcomes. The absolute beneﬁt provided by EES versus PES appears to be proportional to the com-
lexity of coronary disease. (SPIRIT III: A Clinical Evaluation of the Investigational Device XIENCE V Everoli-
us Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary
rtery Lesions [SPIRIT III]; NCT00180479) (SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V
verolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary
rtery Lesions [SPIRIT IV]; NCT00307047) (J Am Coll Cardiol Intv 2010;3:1229–39) © 2010 by the
merican College of Cardiology Foundation
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DES in Single- Versus Multivessel Disease
1230ompared with bare-metal stent (BMS) deployment,
rug-eluting stents (DES) reduce clinical and angio-
raphic restenosis(1,2). The benefits of DES versus BMS
re most apparent in patients with the highest absolute
isk for restenosis (3,4). Despite rapid uptake and utili-
ation of first-generation DES, specific issues related to
heir use have prompted iterative next-generation de-
igns. Relatively thick stent struts and high metal content
f first-generation DES impair deliverability and con-
ormability, increase stent-mediated endoluminal injury,
nd serve as a barrier to endothelialization. In addition,
he risk of late stent thrombosis is increased following
rst-generation DES compared with BMS, necessitating
rolonged dual antiplatelet therapy (5-7).
Finally, although first-generation DES are superior to
MS in reducing restenosis, the requirement for repeat
revascularization remains prob-
lematic and proportional to the
complexity of the coronary disease
(3,8 –10). In this regard, repeat
revascularization rates are still
higher with first-generation DES
than with surgical coronary revas-
cularization in patients with com-
plex multivessel disease (9,10).
To further improve the safety
and efficacy of DES, the Xience
V everolimus-eluting stent (EES)
was developed, and it incorpo-
rates a thin (7.8 m), durable,
biocompatible fluorocopolymer
onto a thin strut (0.0032 in.)
cobalt chromium platform. The
SPIRIT (Clinical Evaluation of
the Xience V Everolimus Elut-
ing Coronary Stent System in
the Treatment of Patients with
de novo Native Coronary Artery
esions) II and III (11,12) trials demonstrated a significant
eduction in quantitative angiographic late lumen loss as well as
oninferior rates of target vessel failure following EES when
ompared with the Taxus Express2 paclitaxel-eluting stent
PES). Although these trials were underpowered to detect
rom the *Christ Hospital, Heart and Vascular Center/The Lindner Research
enter, Cincinnati, Ohio; †Department of Cardiology, Ohio Health Research
nstitute, Riverside Methodist Hospital, Columbus, Ohio; ‡Department of Clinical
esearch, Abbott Vascular, Santa Clara, California; §The Care Group, Heart Center
f Indiana, Indianapolis, Indiana; Cardiac Catheterization Laboratory, The Miriam
ospital, Providence, Rhode Island; and ¶Center for Interventional Vascular Ther-
py, Columbia University Medical Center, The Cardiovascular Research Foundation,
ew York, New York. Dr. Kereiakes received grant and/or research support from
bbott Vascular, Cordis/Johnson & Johnson, Boston Scientific, Medtronic, and
aiichi Sankyo, Inc., and he received consulting fees from Abbott Vascular, Boston
bbreviations
nd Acronyms
MS  bare-metal stent(s)
ABG  coronary artery
ypass graft
ES  drug-eluting stent(s)
ES  everolimus-eluting
tent(s)
D-TLR  ischemia-driven
arget lesion
evascularization
ACE  major adverse
ardiac events
I  myocardial infarction
CI  percutaneous
oronary intervention
ES  paclitaxel-eluting
tent(s)
LF  target lesion failurecientific, Cordis/Johnson & Johnson, Eli Lilly, Medpace, REVA Medical Inc., and
s on the Speakers’ Bureau for Eli Lilly & Co. Dr. Hermiller reports serving as a
M
alinical superiority of EES, the absolute clinical benefits of
ES versus PES through 3-year follow-up have continued to
pread (13,14). Recently, larger, randomized controlled trials,
hich enrolled more complex patient cohorts, have demon-
trated superior clinical benefits of EES when compared with
ither the Taxus Express2 (15) or the second-generation Taxus
iberté (16) PES. To evaluate whether the improved safety
nd efficacy of the EES might translate into superior outcomes
n patients with multivessel disease, we examined the pooled
PIRIT III and IV trials.
ethods
tudy design. The design of the SPIRIT III and IV trials,
hich were both prospective, multicenter, randomized,
ingle-blind, active-controlled studies, have previously been
escribed (12,17). In brief, SPIRIT III randomized 1,002
atients with either 1 or 2 de novo native coronary artery
esions (maximum, 1 lesion per epicardial coronary ar-
ery) in a 2:1 ratio to receive either EES (Xience V,
bbott Vascular, Santa Clara, California) or PES (Taxus
xpress2, Boston Scientific, Natick, Massachusetts), re-
pectively. The SPIRIT IV trial randomized 3,690 pa-
ients with 1, 2, or 3 previously untreated native coronary
rtery lesions (maximum 2 lesions per epicardial vessel) in
2:1 ratio to EES versus PES. Clinical and angiographic
nclusion criteria were similar between studies and in-
luded study lesion diameter stenosis of 50% and
100%, reference vessel diameter 2.5 and 3.75 mm,
nd lesion length 28 mm. In SPIRIT III, bifurcation
esions were only enrolled if the side branch stenosis was
50% and the side branch diameter 2.0 mm. Con-
ersely, in SPIRIT IV, bifurcation lesions with side
ranch stenosis 50% or 2.0-mm diameter were en-
olled. In addition, ostial right coronary stenoses were
ligible for enrollment in SPIRIT IV but not SPIRIT III.
he most substantial difference between trial designs was the
erformance of protocol-specified routine angiographic
ollow-up in 564 patients at 8 months after the index percu-
aneous coronary intervention (PCI) in SPIRIT III, whereas
PIRIT IV had no routine angiographic follow-up. For both
rials, EES were available in diameters of 2.5 to 4.0 mm and
engths of 8, 18, and 28 mm, whereas the full range of
ommercially available PES diameters of 2.5 to 3.5 mm and
onsultant for Abbott Vascular. Dr. Gordon reports having received research support
rom Abbott Vascular and Boston Scientific Corp. Dr. Sudhir, Ms. Ferguson, Dr.
aqub, Dr. Sood, and Ms. Su are employees of Abbott Vascular. Dr. Yakubov reports
erving on the advisory board of Abbott Vascular. Dr. Lansky reports having received
esearch support from Abbott Vascular. Dr. Stone reports serving on the scientific
dvisory boards for and received honoraria from Abbott Vascular and Boston
cientific Corp.anuscript received May 28, 2010; revised manuscript received August 26, 2010,
ccepted September 3, 2010.
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1231engths of 8, 12, 16, 20, 24, 28, and 32 mm were used. Both
tudies were approved by the institutional review boards at
articipating centers, and consecutive eligible patients signed
nformed consent.
edication administration and clinical follow-up. In both
rials, aspirin 300 mg was administered before catheter-
zation and an oral clopidogrel load of 300 mg was
ecommended before the procedure and required within 1 h
fter stent implantation. In both trials, aspirin 80 mg was
dministered daily indefinitely, and clopidogrel 75 mg daily
as prescribed for 6 months (SPIRIT III) or for 12
onths (SPIRIT IV). In both trials, clinical follow-up was
cheduled at 3, 180, 240, 270, and 365 days and then yearly
hrough 5 years.
linical end points and deﬁnitions. End point definitions
ave been described previously and were similar in both
rials (12,17). Target lesion failure (TLF at 1 year was
efined as the composite of cardiac death, target vessel
yocardial infarction (MI), or ischemia-driven target lesion
evascularization (ID-TLR) by either PCI or coronary
rtery bypass graft (CABG) surgery. The individual compo-
ents of TLF have been defined previously (17). Additional
nd points for analysis included the composite of cardiac death
r target vessel MI; ID-TLR; major adverse cardiac events
MACE), defined as the composite of cardiac death, MI, or
D-TLR; target vessel failure, defined as the composite of
ardiac death, MI, or ID-target vessel revascularization; and
tent thrombosis, which was adjudicated using the Academic
esearch Consortium definite or probable criteria (18).
tatistical analysis. Because the examination of subgroup data
s inherently underpowered, the SPIRIT III and IV databases
Figure 1. SPIRIT III/IV Pooled Analysis Study Flow Diagram
Subjects are stratiﬁed by randomly assigned stent type (EES vs. PES) as well as
SPIRIT III trial was excluded from this analysis. EES  everolimus-eluting stent;
RVD  reference vessel diameter; SPIRIT III  Clinical Evaluation of the Xience V E
Native Coronary Artery Lesions III trial.ere pooled, which was justified by similar inclusion/exclusion
riteria, randomization ratios, end point definitions, and clin-
cal follow-up schedules. Pooling of patient-level data from
oth trials yielded 4,692 randomized patients.
Binary variables are presented as percentages and were
ompared by Fisher exact test. Continuous variables are
resented as mean  SD and were compared by t test. All
ata are presented in the intent-to-treat population, con-
isting of all patients randomized, regardless of the treat-
ent actually received. However, patients lost to follow-up
n whom no event had occurred were not included in the
enominator for calculations of binary end points. Survival
urves using all available follow-up data were also con-
tructed for time-to-event variables using Kaplan-Meier
stimates and compared by log-rank test. A 2-sided alpha
.05 was used for all superiority testing. All p values are
isplayed for descriptive (hypothesis-generating) purposes.
ll statistical analyses were performed by SAS (version
.1.3, SAS Institute, Cary, North Carolina).
esults
tudy population. The study populations from both
PIRIT III (n  1,002) and SPIRIT IV (n  3,690) have
een described previously (12,17). One patient from
PIRIT III was excluded from the final analysis, and 3
atients were excluded from SPIRIT IV who were random-
zed in error and not treated. The combined study popula-
ion included 4,689 patients who were randomly assigned
:1 to receive EES (n  3,127) or PES (n  1,562).
ingle-vessel PCI was performed in 3,903 patients (83%),
er of vessels and lesions treated (single vs. multiple). *One PES patient in
lesion length; lsns  lesions; PES  paclitaxel-eluting stent(s); pts  patients;
us Eluting Coronary Stent System in the Treatment of Patients with De Novonumb
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1232hereas 785 patients (17%) underwent multivessel PCI.
tudy flow is illustrated in Figure 1. Patients were further
tratified for analysis according to treatment of a single
esion (n  3,614; 77%) or multiple lesions (n  1,074;
3%). Both baseline clinical (Table 1) and angiographic
Table 2) features were similar between the randomly
ssigned stent cohorts in the various groups with the sole
xception that lesion length was slightly longer in single-
essel patients treated with EES versus PES (14.8  6.4 vs.
4.3  6.2; p  0.04).
rocedural results. The number of lesions treated was sim-
lar by randomly assigned stent type for patients with single-
r multivessel disease (Table 3). Because of the trial design’s
imitation of stent lengths available for EES (3 lengths)
ersus PES (7 lengths), the numbers of stents deployed per
atient and per lesion were slightly greater in patients
Table 1. Baseline Demographics in Patients With Single- and Multivessel T
Single-Vessel Treatmen
EES PES
Demographic Features (n  2,616 Patients) (n  1,287 Pat
Age, yrs 63.2 10.6 63.2 10.
Male 67.4 66.0
Current smoker 21.6 21.8
Hypertension 77.4 75.8
Hypercholesterolemia 76.7 74.7
Diabetes mellitus 30.9 30.9
Insulin requiring 8.0 8.9
All prior cardiac interventions 33.0 32.3
On target vessel 10.4 9.4
Unstable angina 25.7 27.5
Prior myocardial infarction 21.2 20.2
Values are mean SD or %.
EES everolimus-eluting stent(s); PES paclitaxel-eluting stent(s).
Table 2. Target Lesion Characteristics in Patients With Single- and Multive
Single-Vessel Treatme
Target Lesion Characteristics
EES PES
(n  2,821 Lesions) (n  1,375 L
Coronary artery location
Left anterior descending 42.4 42.3
Left circumﬂex 22.8 23.6
Right 34.8 34.1
ACC/AHA lesion class B2 and C 50.7 47.9
Calciﬁcation (moderate or severe) 26.8 25.9
Reference vessel diameter, mm 2.8 0.5 2.8 0
Minimal luminal diameter, mm 0.8 0.4 0.8 0
Diameter stenosis 72.2 12.8 71.7 1
Lesion length, mm 14.8 6.4 14.3 6
Values are % or mean SD.ACC American College of Cardiology; AHA American Heart Association; other abbreviations as in Tassigned to EES. Both total stent length per lesion treated
nd total stent length/lesion length ratios were significantly
igher in EES versus PES treated subjects irrespective of
he number of vessels treated.
ntiplatelet agent use. Antiplatelet agent compliance was
imilar among patients in both single- and multivessel
reatment groups and between EES and PES treatment
rms. In the single-vessel treatment group, 88.1% of EES
nd 87.5% of PES patients (p  0.63) remained on dual
aspirin plus thienopyridine) therapy at 1 year. In the
ultivessel treatment group, 90.2% of EES and 91.8% of
ES patients (p  0.51) remained on dual therapy at 1
ear.
ingle- versus multivessel treatment. The cumulative inci-
ence of TLF and its individual components are shown
tratified by stent type and number of treated vessels in
ent
Multivessel Treatment
EES PES
p Value (n  511 Patients) (n  274 Patients) p Value
0.84 63.6 10.2 63.1 10.6 0.56
0.39 72.4 73.4 0.80
0.90 25.0 25.3 0.93
0.28 75.9 75.2 0.86
0.18 70.2 74.7 0.18
1.00 34.7 34.4 1.00
0.36 10.0 8.1 0.44
0.69 24.8 21.6 0.33
0.39 15.0 12.3 0.33
0.24 25.9 30.4 0.18
0.50 19.0 15.9 0.32
reatment
Multivessel Treatment
EES PES
) p Value (n  1,093 Lesions) (n  593 Lesions) p Value
0.97 36.1 36.1 1.00
0.58 30.1 31.5 0.58
0.65 33.8 32.4 0.59
0.09 50.4 48.6 0.51
0.58 24.4 24.5 0.95
0.69 2.7 0.5 2.7 0.5 0.12
0.27 0.8 0.4 0.8 0.4 0.93
0.22 70.8 12.7 71.0 13.0 0.76
0.04 14.8 6.6 15.1 6.9 0.32reatm
t
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1233able 4. The 1-year rate of TLF was reduced by EES
ompared with PES in both single- and multivessel
reatment groups. Although the Kaplan-Meier curves for
LF event occurrence through 1 year demonstrate ap-
arent numerically greater relative benefit of EES versus
ES in the multivessel compared with single-vessel
reatment group (52% vs. 36% reduction) (Figs. 2A and
B), a statistically significant interaction was not present
p  0.30). Cardiac death rates at 1 year were similar by
tent type for both single- and multivessel treatment
roups. The rates of target vessel MI at 1 year were
omparable by stent type for single- but not for multives-
el treatment patients, in whom target vessel MI was
ignificantly reduced by EES compared with PES (2.2%
s. 6.1%; p  0.007). This observation drove a numeri-
ally greater relative reduction in the composite occur-
ence of cardiac death or target vessel MI in favor of EES
n patients undergoing multivessel PCI (57% reduction;
 0.02) compared with single-vessel PCI (18% reduc-
ion; p  0.36) (Figs. 3A and 3B), although the p value
or interaction did not achieve statistical significance
Table 3. Procedural Results in Patients With Single- and Multivessel Treat
Single-Vessel Treatment
EES PES
Procedural Variables
(n  2,616 Patients)
(n  2,821 Lesions)
(n  1,287 Pat
(n  1,375 Les
Patients with multiple lesions 7.7 6.8
Number of lesions per patient 1.08 0.27 1.07 0.2
Number of stents per patient 1.25 0.53 1.20 0.4
Number of stents per lesion 1.16 0.43 1.13 0.3
Total stent length per lesion 22.36 8.58 20.74 8.1
Total stent lesion length ratio 1.63 0.61 1.56 0.5
Values are % or mean SD.
N/A nonapplicable; other abbreviations as in Tables 1 and 2.
Table 4. Clinical Outcomes at 1 Year in Patients With Single- and Multives
Single-Vessel
(n  3,903
EES
(n  2,616 Patients) (n 
Target lesion failure 4.1% (106 of 2,571) 6.4
Cardiac death 0.4% (11 of 2,571) 0.4
Target vessel myocardial infarction 1.8% (47 of 2,571) 2.4
Q-wave 0.2% (4 of 2,571) 0.2
Non–Q-wave 1.7% (43 of 2,571) 2.2
Ischemia-driven target lesion revascularization 2.4% (62 of 2,571) 4.2
Major adverse cardiac events 4.3% (110 of 2,571) 6.5
Stent thrombosis (ARC deﬁnite/probable) 0.3% (7 of 2,546) 0.6ARC Academic Research Consortium; other abbreviations as in Table 1.p  0.12). Although ID-TLR was increased for both
tent types in the multivessel compared with the single-
essel treatment group, the relative benefit of EES versus
ES was comparable (49% vs. 43%, respectively) (Figs.
A and 4B). Similarly, the rates of both MACE and stent
hrombosis were increased in the multivessel PCI com-
ared with the single-vessel PCI group. The relative
eduction in MACE provided by EES versus PES was
umerically greater in the multivessel group (50% vs. 34%
ingle-vessel group), although the p value for interaction
as not significant (p  0.28). For Academic Research
onsortium– defined definite/probable stent thrombosis,
he relative reduction, EES versus PES, was similar
etween the single- and multivessel groups (50% single
s. 56% multivessel), with a nonsignificant p value for
nteraction (p  0.96). One-year nonhierarchical rates of
ardiac death, Q-wave and non–Q-wave MI, as well as
LR stratified by stent type and number of treated vessels
re shown (Fig. 5).
ingle- versus multilesion treatment. Clinical outcomes
tratified by stent type and number of treated lesions are
Multivessel Treatment
EES PES
p Value
(n  511 Patients)
(n  1,093 Lesions)
(n  274 Patients)
(n  593 Lesions) p Value
0.36 100.0 100.0 NA
0.26 2.14 0.35 2.16 0.37 0.35
0.006 2.52 0.78 2.49 0.78 0.57
0.010 1.19 0.45 1.15 0.43 0.08
0.0001 22.78 9.33 21.69 9.89 0.03
0.0003 1.68 0.85 1.52 0.73 0.0001
eatment
ent
ts)
Multivessel Treatment
(n  785 Patients)
S EES PES
Patients) p Value (n  511 Patients) (n  274 Patients) p Value
f 1,252) 0.003 6.0% (30 of 502) 12.2% (32 of 263) 0.005
f 1,252) 1.00 0.8% (4 of 502) 1.1% (3 of 263) 0.70
f 1,252) 0.27 2.2% (11 of 502) 6.1% (16 of 263) 0.007
f 1,252) 0.69 0.2% (1 of 502) 1.1% (3 of 263) 0.12
f 1,252) 0.25 2.0% (10 of 502) 4.9% (13 of 263) 0.04
f 1,252) 0.004 4.2% (21 of 502) 8.0% (21 of 263) 0.04
f 1,252) 0.003 6.2% (31 of 502) 12.5% (33 of 263) 0.004
f 1,238) 0.10 1.2% (6 of 495) 2.7% (7 of 259) 0.15ment
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ions)
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1234hown (Table 5). The relative magnitude of clinical benefit
rovided by EES (vs. PES) was again greater in patients
reated with multilesion (vs. single-lesion) disease.
iscussion
he clinical prognosis for patients with multivessel disease
ollowing PCI is worse than for those with single-vessel
isease (19,20). Although randomized trials have shown
hat DES reduce clinical and angiographic restenosis when
ompared with BMS (1,2), few trials have included patients
Figure 2. TLF to 1 Year
Kaplan-Meier time-to-event curves showing target lesion failure rates through 1 ye
multivessel treatment. CI  conﬁdence interval; HR  hazard ratio; TLF  target lith multivessel coronary artery disease (21–23). In con- Crast, multiple observational registries have demonstrated
he benefits of DES compared with BMS in real-world
atients with multivessel disease and/or those treated for
off-label” indications (1-3). However, these observational
tudies are often confounded by selection bias and covariate
both known and unknown) imbalances. Nonetheless, the
se of DES for treatment of multivessel coronary disease has
merged as an alternative to CABG, which is the estab-
ished gold standard for these patients. Whether this prac-
ice is justified remains controversial.
In the recent SYNTAX (Synergy Between Percutaneous
EES vs. PES in: (A) patients with single-vessel treatment and (B) patients with
ailure; other abbreviations as in Figure 1.ar fororonary Intervention with Taxus and Cardiac Surgery)
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1235rial, 1,800 patients with 3-vessel and/or left main coronary
rtery disease were randomly assigned to either PCI using
ES or CABG (9). The primary end point of major adverse
ardiovascular and cerebrovascular events (composite occur-
ence of all-cause death, stroke, MI, or repeat revascular-
zation) was significantly increased to 12 months following
CI compared with CABG. Major adverse cardiovascular
nd cerebrovascular events were directly proportional to the
omplexity of underlying coronary disease as determined by
ertile of SYNTAX score (measure of angiographic com-
lexity) following PCI but not CABG. The increase in
ajor adverse cardiovascular and cerebrovascular events
Figure 3. Cardiac Death or Target Vessel MI to 1 Year
Kaplan-Meier time-to-event curves showing the composite occurrence of cardi
single-vessel treatment and (B) patients with multivessel treatment. MI  myoollowing PCI was largely explained by an increased require- aent for repeat revascularization (13.5% PCI vs. 5.9%
ABG; p  0.001) that was not associated with a concom-
tant increase in the rate of death or MI. Indeed, CABG was
ssociated with an increased incidence of stroke (2.2%) com-
ared with PCI (0.6%; p  0.003). However, the SYNTAX
rial was underpowered for these low-frequency safety events,
nd CABG remains the gold standard for most patients with
eft main and complex multivessel disease.
The present large-scale randomized comparison of EES
ersus PES in patients with multivessel disease has relevance
s to whether superior results might be obtained in patients
ith complex coronary artery disease undergoing PCI with
th or target vessel MI through 1 year for EES vs. PES in: (A) patients with
l infarction; other abbreviations as in Figures 1 and 2.ac dean improved stent platform. The major results of note in the
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1236resent study are that: 1) The incidences of target vessel MI
nd composite cardiac death or MI to 1 year were signifi-
antly reduced by EES compared with PES. 2) The
ncidence of ID-TLR to 1 year was reduced by EES versus
ES, particularly in those subjects with multivessel/
ultilesion treatment. 3) The absolute benefit afforded by
ES compared with PES was proportional to the complex-
ty of coronary disease as reflected by either the number of
essels or lesions treated. 4) The incremental benefit in both
I and ID-TLR with EES in complex coronary disease
as also reflected by reductions in the composite safety and
fficacy end points of TLF and MACE. These clinical end
Figure 4. ID-TLR to 1 Year
Kaplan-Meier time-to-event curves showing ischemia-driven TLR rates through
with multivessel treatment. ID  ischemia-driven; TLR  target lesion revasculoints have relevance to the results of the SYNTAX trial Snd suggest that EES may enhance both the relative safety
composite of death, MI, or stroke) and efficacy (repeat
evascularization) of PCI compared with CABG.
The observations in the present study regarding the
elative safety and efficacy of EES versus PES are supported
y data from recent randomized controlled trials and clinical
egistries. Applegate et al. (8) previously reported from the
PIRIT III trial that at 2-year follow-up, patients treated
or 2-vessel disease with EES rather than PES had a relative
eduction in target vessel failure (by 35%) and MACE (by
1%). More recently, in the COMPARE (Second-
eneration Everolimus-Eluting and Paclitaxel-Eluting
r for EES vs. PES in: (A) patients with single-vessel treatment and (B) patients
on; other abbreviations as in Figures 1, 2, and 3.1 yeatents in Real-Life Practice) trial (16), 1,800 real-world
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1237atients (60% acute coronary syndrome, 25% ST-segment
levation MI, 27% multivessel treatment with an average
.4  0.7 lesions treated per patient) were randomly
ssigned to treatment with either EES or the Taxus Liberté
ES. The absolute benefit of EES versus PES for reduction
f MACE (composite of death, nonfatal MI, ID target
essel revascularization) was greater in multivessel (8.0% vs.
3.0%, respectively) compared with single-vessel (6.0% vs.
%, respectively) disease patients. In the COMPARE trial,
oth ID-TLR (2% EES vs. 5% PES; p  0.0002) and stent
hrombosis (Academic Research Consortium–defined definite
r probable definition) were reduced by EES (0.7% vs. 3.0%
ES; p  0.002), which is similar to the SPIRIT III and IV
rials. Thus, the cumulative experience in 4,689 patients
Figure 5. Clinical Outcomes Stratified by Angiographic Complexity and Ste
One-year nonhierarchical rates of cardiac death, target vessel Q-wave myocard
lesion revascularization for everolimus- versus paclitaxel-eluting stent(s) stratiﬁ
Table 5. Clinical Outcomes at 1 Year in Patients With Single- and Multiles
Single-Lesion
(n  3,614
EES
(n  2,415 Patients) (n 
Target lesion failure 4.1% (98 of 2,371) 6.2
Cardiac death 0.5% (11 of 2,371) 0.4
Target vessel myocardial infarction 1.8% (43 of 2,371) 2.3
Q-wave 0.1% (3 of 2,371) 0.3
Non–Q-wave 1.7% (40 of 2,371) 2.1
Ischemia-driven target lesion revascularization 2.4% (57 of 2,371) 4.0
Major adverse cardiac events 4.3% (102 of 2,371) 6.4
Stent thrombosis (ARC deﬁnite/probable) 0.3% (6 of 2,346) 0.6Abbreviations as in Tables 1, 2, 3, and 4.ndergoing both elective and nonelective PCI enrolled into the
PIRIT III (14), SPIRIT IV (15), or COMPARE trials (16)
ho were randomly assigned to treatment with EES or PES
emonstrates substantial clinical benefit of EES with respect to
easures of both safety and efficacy.
tudy limitations. Several limitations of this study should be
cknowledged. First, despite the relatively large number of total
atients in the present analysis, sample sizes in individual
ubgroups may still be insufficient to derive reliable estimates of
tent thrombosis or other low frequency occurrence events.
econd, the availability of only 3 stent lengths for EES versus
stent lengths for PES limited the ability to “tailor” stent
ength-to-target lesion length in EES-treated patients. As a
esult, the average stent length/lesion as well as the stent
e
arction (QMI) or non–Q-wave myocardial infarction (NQMI) as well as target
single- or multivessel treatment. Abbreviations as in Figures 1, 2, 3, and 4.
eatment
ent
ts)
Multilesion Treatment
(n  1,074 Patients)
S EES PES
Patients) p Value (n  712 Patients) (n  362 Patients) p Value
f 1,165) 0.009 5.4% (38 of 702) 11.4% (40 of 350) 0.0007
f 1,165) 1.00 0.6% (4 of 702) 0.9% (3 of 350) 0.69
f 1,165) 0.31 2.1% (15 of 702) 5.4% (19 of 350) 0.008
f 1,165) 0.40 0.3% (2 of 702) 0.9% (3 of 350) 0.3
f 1,165) 0.35 1.9% (13 of 702) 4.6% (16 of 350) 0.02
f 1,165) 0.008 3.7% (26 of 702) 7.4% (26 of 350) 0.01
f 1,165) 0.01 5.6% (39 of 702) 11.7% (41 of 350) 0.0008
f 1,151) 0.14 1.0% (7 of 695) 2.3% (8 of 346) 0.10nt Typ
ial infion Tr
Treatm
Patien
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1238ength-to-lesion length ratios were greater with EES than
ES. As longer DES stent lengths have directly been corre-
ated with the risk for stent thrombosis, MI and ID-TLR
5,21,24-26), the relative benefit provided by EES versus PES
ight even be further improved by the available wide range of
ES stent lengths and diameters. In addition, it should be
oted that in the SYNTAX trial, the average number of target
esions treated per patient was 3.6 compared with either the
ingle- (1.08 lesions) or multivessel (2.15 lesions) treatment
roups in the present analysis. The small numbers of patients
ndergoing PCI in all 3 vessels (n  24) or of 3 lesions (n 
20) in the present study precludes meaningful separate anal-
sis. Thus, randomized trials of PCI with EES versus CABG
re required to determine if the outcomes with EES are
ufficiently improved to supplant surgery in patients with the
ost coronary anatomy. Finally, although the benefit attribut-
ble to EES versus PES appears to be directly proportional to
he complexity of coronary disease being treated, a statistical
nteraction by stent type was not demonstrated, and even the
ooled analysis remains underpowered to allow definitive
onclusions regarding relative efficacy.
onclusions
he limitations notwithstanding, in the present pooled
nalyses of 4,689 patients enrolled into the SPIRIT III and
V trials who were randomized to treatment with EES or
ES, EES provided substantial clinical safety and efficacy
enefits compared with PES. Furthermore, the absolute
enefit of EES versus PES was directly proportional to the
omplexity of coronary artery disease as reflected by either
he number of target vessels or lesions treated. These
bservations may have significant implications with respect
o the optimal choice of revascularization strategy (PCI vs.
ABG) in patients with multivessel coronary disease.
eprint requests and correspondence: Dr. Dean J. Kereiakes,
he Christ Hospital Heart and Vascular Center, 2123 Auburn
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